Novo Nordisk A/S (NVO) Receives Tender Offer for 2M Shares

Novo Nordisk A/S (NYSE:NVO) is one of the best depressed stocks to buy in 2025. On August 4, the company confirmed it had received an unsolicited mini-tender offer from TRC Capital Investment Corporation.

Novo Nordisk A/S (NVO) Receives Tender Offer for 2M Shares

Pixabay/Public Domain

The mini tender offer is for the purchase of up to 2 million American Depositary shares representing less than 0.045% of its total share capital. Novo Nordisk management remains neutral in the tender offer and has advised shareholders to exercise caution and consult financial advisors.

Given that the tender offer covers an immaterial stake, there will be no change in Novo Nordisk’s control or capital structure.

Novo Nordisk A/S (NYSE:NVO) is a healthcare company that develops and delivers innovative treatments for serious chronic diseases, with a particular emphasis on diabetes and obesity. It also develops treatments for rare blood and endocrine diseases, haemophilia, and growth disorders.

While we acknowledge the potential of NVO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Medical AI Companies to Buy According to Analysts and 10 Best Rare Earth Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.